ALung Technologies brings in $2.6m
Artificial lung-like device developer ALung Technologies has raised $2.6 million in a new round of financing, according to an SEC filing posted this week. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. Money in the round so far has come from 36 anonymous investors, with the company seeking another $1.4 million before closing the debt and option round, according to the SEC filing. The company has not yet stated how it intends to use funds raised in the round. Last January, ALung Technologies reported raising $10.8 million in a round of debt financing. A month earlier, the company said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure. The U.K.’s National Institute for Health Research will supply $3.1 million (GBP £2.1 million) in funding for the 1,120 patient Rest trial, which looks to examine the effect of protective ventilation with veno-venous lung assist devices during respiratory failure. The trial will be jointly led by Queen’s University and Belfast Health and Social Services Trust, the company said. The post ALung Technologies brings in $2.6m appeared first on MassDevice.
Researchers from Saudi Arabia have created 3D-printed models based on the CT...Read more on AuntMinnie.comRelated Reading: 3D printing reduces liver transplant costs, surgery time 3D printing yields custom-fit glasses for kids 3D printing helps separate rare case of conjoined twins 3D printing gives pediatric heart surgery a boost 3D-printed lungs improve patient understanding of surgery
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
ConclusionsBTT ECMO can be performed as a bridge to LTx without significantly increasing patient mortality in high-volume centers. Patients undergoing BTT ECMO at LTx centers that perform more than 35 LTx annually have equivalent mortality to those who do not require ECMO prior to transplantation.Graphical abstract
Publication date: May 2019Source: American Journal of Kidney Diseases, Volume 73, Issue 5Author(s):
Authors: Shigemura N PMID: 30997234 [PubMed]
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
The new heart allocation system in the United States prioritizes patients supported by temporary mechanical circulatory support devices (TMCS) over those with uncomplicated durable continuous-flow left ventricular assist devices (CF-LVAD), which may increase the number of patients bridged to transplant with TMCS. Limited data are available in guiding post-transplant outcomes with various TMCS devices. We sought to describe post-transplant outcome and identify clinical variables associated with post-transplant outcome in patients bridged to transplant with TMCS.
We describe a novel approach for bilateral lung transplantation as off-pump technique via median sternotomy which has the potential to combine the advantages of median sternotomy with less postoperative pain and better chest wall function and off-pump technique with reduced risk of primary graft dysfunction and bleeding complications.
(Reuters Health) - In many parts of the world there are not enough radiation oncologists to design and deliver radiation treatments for lung cancer patients, but that gap could one day be filled with the help of artificial intelligence, researchers suggest in a new study.
In conclusion, a reliable and robust LC-MS/MS method was developed to quantify erlotinib in hair, however, clinical and in vitro evaluations showed that the method is not suitable for monitoring long term erlotinib exposure. The pitfalls of this application outweigh the current benefits.